Skip to main content

Table 3 Logistic regression analyses for risk factors of hypermagnesemia in patients prescribed MgO

From: Risk factors for the development of hypermagnesemia in patients prescribed magnesium oxide: a retrospective cohort study

Variables

Univariate analysis

Multivariate analysis

Odds ratio

95% CI

P value

Odds ratio

95% CI

P value

Age ≥ 68 years

2.548

1.498–4.330

< 0.001

1.710

0.937–3.123

0.081

eGFR ≤55.4 mL/min

4.564

2.624–7.938

< 0.001

3.105

1.642–5.872

0.001

BUN ≥22.4 mg/dL

4.793

2.580–8.940

< 0.001

3.490

1.762–6.911

< 0.001

MgO dose ≥1650 mg/day

2.004

1.175–3.418

0.011

1.914

1.034–3.542

0.039

Duration of MgO administration ≥36 days

2.074

1.201–3.580

0.009

2.198

1.190–4.060

0.012

Co-administrated drugs

 PPIs

1.061

0.629–1.791

0.825

 

 H2 blocker (famotidine)

1.999

0.757–5.275

0.162

0.538

0.175–1.657

0.280

 VD3 drugs

1.417

0.357–5.620

0.620

 

 Diuretics

1.831

0.744–4.504

0.188

1.348

0.471–3.863

0.578

  1. BUN blood urea nitrogen, CI confidence interval, eGFR estimated glomerular filtration rate, MgO magnesium oxide, PPIs proton pump inhibitors, VD3 vitamin D3